A Single-Institutional Phase IIa Trial and A Multi-Institutional Phase IIb Trial of Apatinib in Metastatic Triple-Negative Breast Cancer.
Phase of Trial: Phase II
Latest Information Update: 11 Sep 2015
At a glance
- Drugs Rivoceranib (Primary)
- Indications Advanced breast cancer
- Focus Therapeutic Use
- 08 Sep 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 02 Dec 2013 Planned number of patients changed from 80 to 60 as reported by ClinicalTrials.gov.
- 02 Dec 2013 Planned end date changed from 1 Dec 2013 to 1 Jun 2015 as reported by ClinicalTrials.gov.